×
About 11,223 results

ALLMedicine™ Non-Hodgkin Lymphoma Center

Research & Reviews  3,579 results

New Directions for Mantle Cell Lymphoma in 2022.
https://doi.org/10.1200/EDBK_349509
American Society of Clinical Oncology Educational Book. A... Kumar A, Eyre TA et. al.

May 14th, 2022 - Mantle cell lymphoma is a rare B-cell non-Hodgkin lymphoma that is clinically and biologically heterogeneous. Risk stratification at the time of diagnosis is critical. One of the most powerful prognostic indices is the Mantle Cell Lymphoma Interna...

Novel strategies for relapsed/refractory DLBCL; navigating the immunotherapy era in agg...
https://doi.org/10.1080/10428194.2022.2068007
Leukemia & Lymphoma; Gordon MJ, Sureda A et. al.

May 14th, 2022 - Diffuse large B-cell lymphoma (DLBCL) is the most common type of aggressive non-Hodgkin lymphoma. Combination chemotherapy with immunotherapy can be curative, however, nearly one-third of patients will have a disease that is refractory or will rel...

Long-term exposure to wildfires and cancer incidence in Canada: a population-based obse...
https://doi.org/10.1016/S2542-5196(22)00067-5
The Lancet. Planetary Health; Korsiak J, Pinault L et. al.

May 14th, 2022 - Wildfires emit many carcinogenic pollutants that contaminate air, water, terrestrial, and indoor environments. However, little is known about the relationship between exposure to wildfires and cancer risk. We aimed to assess the associations betwe...

Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma
https://clinicaltrials.gov/ct2/show/NCT03479268

May 13th, 2022 - PRIMARY OBJECTIVES: I. To evaluate the safety and tolerability of pevonedistat administered in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL). SECONDARY OBJECTIV...

Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT03739827

May 13th, 2022 - Background: Rare tumors are defined as fewer than 150 incident cases per one million per year. Consequently, only 11 tumor types are common in U.S. adults (prostate, breast, lung/bronchus, colon, uterus, bladder, melanoma, rectum, ovary, non-Hodgk...

see more →

Guidelines  4 results

UK Guidelines on the Diagnosis and Treatment of Breast Implant-Associated Anaplastic La...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7894347
British Journal of Haematology; Turton P, El-Sharkawi D et. al.

Nov 23rd, 2020 - Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is an uncommon T-cell non-Hodgkin Lymphoma (NHL) associated with breast implants. Raising awareness of the possibility of BIA-ALCL in anyone with breast implants and new breast sy...

Pediatric Aggressive Mature B-Cell Lymphomas, Version 2.2020, NCCN Clinical Practice Gu...
https://doi.org/10.6004/jnccn.2020.0036
Journal of the National Comprehensive Cancer Network : JN... Davies K, Barth M et. al.

Aug 7th, 2020 - Pediatric aggressive mature B-cell lymphomas are the most common types of non-Hodgkin lymphoma in children, and they include Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL). These diseases are highly aggressive but curable, the tre...

Practical recommendations for fertility preservation in women by the FertiPROTEKT netwo...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762797
Archives of Gynecology and Obstetrics; Schüring AN, Fehm T et. al.

Nov 28th, 2017 - Most guidelines about fertility preservation are predominantly focused on scientific evidence, but are less practically orientated. Therefore, practically oriented recommendations are needed to support the clinician in daily practice. A selective ...

Rituximab in Lymphoma and Chronic Lymphocytic Leukaemia: A Practice Guideline.
https://doi.org/10.1016/j.clon.2016.09.004
Clinical Oncology (Royal College of Radiologists (Great B... Prica A, Baldassarre F et. al.

Oct 18th, 2016 - Rituximab is the first monoclonal antibody to be approved for use by the US Food and Drug Administration in cancer. Its role in the treatment of non-Hodgkin lymphoma, including chronic lymphocytic leukaemia (CLL), has evolved significantly. We aim...

see more →

Drugs  59 results see all →

Clinicaltrials.gov  183 results

Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT03739827

May 13th, 2022 - Background: Rare tumors are defined as fewer than 150 incident cases per one million per year. Consequently, only 11 tumor types are common in U.S. adults (prostate, breast, lung/bronchus, colon, uterus, bladder, melanoma, rectum, ovary, non-Hodgk...

A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
https://clinicaltrials.gov/ct2/show/NCT00967785

May 13th, 2022 - Mozobil (TM) (plerixafor injection, Genzyme/Sanofi) is a Food and Drug Administration approved medication to mobilize CD34+ hematopoietic stem cells prior to apheresis and use in autologous transplantation in non-Hodgkin lymphoma and multiple myel...

Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma
https://clinicaltrials.gov/ct2/show/NCT03479268

May 13th, 2022 - PRIMARY OBJECTIVES: I. To evaluate the safety and tolerability of pevonedistat administered in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL). SECONDARY OBJECTIV...

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT04739813

May 13th, 2022 - Background: Combination chemotherapy with rituximab has been the mainstay of treatment for CD20-positive B-cell lymphomas. Significant advances have been made in curing aggressive B-cell lymphomas with chemoimmunotherapy, but indolent lymphomas an...

Study to Evaluate CCS1477 in Haematological Malignancies
https://clinicaltrials.gov/ct2/show/NCT04068597

May 13th, 2022 - A Phase 1/2a study to assess the safety, tolerability, PK and biological activity of CCS1477 in patients with Non-Hodgkin Lymphoma, Multiple Myeloma, Acute Myeloid Leukaemia or High Risk Myelodysplastic syndrome.

see more →

News  663 results

Ublituximab/Umbralisib BLA/sNDA in CLL and SLL Voluntarily Withdrawn
https://www.onclive.com/view/ublituximab-umbralisib-bla-snda-in-cll-and-sll-voluntarily-withdrawn

May 6th, 2022 - The pending biologics license application (BLA) and supplemental new drug application (sNDA) seeking the approval of the combination of ublituximab and umbralisib (Ukoniq; U2) in adult patients with chronic lymphocytic leukemia (CLL) and small lym...

Dr. Westin on the Evolving Landscape of CAR T-Cell Therapy in NHL
https://www.onclive.com/view/dr-westin-on-the-evolving-landscape-of-car-t-cell-therapy-in-nhl

May 3rd, 2022 - Jason R. Westin, MD, director, Lymphoma Clinical Research, section chief, Aggressive Lymphoma, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the evolv...

Dr. Bezerra on Barriers to Enrollment for Clinical Trials in B-Cell NHL
https://www.onclive.com/view/dr-bezerra-on-barriers-to-enrollment-for-clinical-trials-in-b-cell-nhl

Apr 26th, 2022 - Evandro D. Bezerra, MD, clinical fellow of Hematology, Mayo Clinic, discusses barriers to enrollment in clinical trials for patients with aggressive B-cell non-Hodgkin lymphoma (NHL) who have progressed on anti-CD19 CAR T-cell therapy. This patie...

Liso-cel Continues to Demonstrate Clinical Responses in Relapsed/Refractory LBCL at 2-Year Follow-Up
https://www.onclive.com/view/liso-cel-continues-to-demonstrate-clinical-responses-in-relapsed-refractory-lbcl-at-2-year-follow-up

Apr 25th, 2022 - The utilization of lisocabtagene maraleucel (liso-cel; Breyanzi) in patients with relapsed/refractory large B-cell lymphomas (LBCL) produced durable outcomes at a 2 years follow-up, according to results from the phase 1 TRANSCEND NHL 001 trial (NC...

CAR NK Cell Therapies Show Preliminary Safety and Efficacy in AML, Non-Hodgkin Lymphoma
https://www.onclive.com/view/car-nk-cell-therapies-show-preliminary-safety-and-efficacy-in-aml-non-hodgkin-lymphoma

Apr 25th, 2022 - The novel allogeneic CAR-engineered natural killer (NK) cell therapies, NKX101 and NKX01, showcased early signs of safety and efficacy when utilized in the treatment of heavily pretreated patients with acute myeloid leukemia (AML) and non-Hodgkin ...

see more →

Patient Education  1 results see all →